SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Siemens' new CT gets FDA nod New opportunity for freestanding ERs

ASTRO 2014 - resounding success The 2014 show and conference brought a lot to the table

ASTRO and AANS team-up on SRS patient registry The stereotactic radiosurgery patient registry will utilize 30 participating facilities

Varian rolls out InSightive Analytics at ASTRO, an interactive visualization solution The tool gives users of the ARIA information system powerful data analysis capabilities

Single fraction is just as good at multiple fraction radiation therapy ASTRO presents breakthrough study

Siemens shows MR & CT solutions at ASTRO optimized for radiation oncology The company innovates advances in the practice of radiation therapy (RT)

Accuray puts technology on display at ASTRO The company showcased the latest in TomoTherapy and CyberKnife technology

Varian's software support for Siemens' Modulated Arc (mARC) highlighted at ASTRO Varian treatment planning software now available to oncology facilities using Siemens LINACs

The shifting medical practice may decrease access to care More patients insured but doctors are at full capacity

MEDICA 2014: robotics in the cardiology field Events highlight new advances

IBA spins off radiopharmaceutical division

by Brendon Nafziger , DOTmed News Associate Editor
New York private equity firm SK Capital Partners bought a controlling stake in Ion Beam Applications S.A.'s radiopharmaceutical division, which is being spun off into its own company, IBA announced Monday. Under the terms of the new deal, SK Capital will own 60 percent of the new business, called IBA Molecular Imaging, and IBA will retain a 40 percent stake.

The transaction, expected to close in the second quarter, is valued at 180 million euros ($229 million). IBA said it expects to net 100 million euros ($127 million) from the deal after debt adjustments, although the sale will result in "significant exceptional loss" for 2011 accounts as the transaction "does not value the IBA radiopharmaceutical business at the level previously booked in its consolidated statements," the company said in a statement.

Story Continues Below Advertisement

Can a small footprint have a big impact in DR?

The Multix Select digital radiography (DR) system's floor mounting, table integrated generator & small footprint can accommodate even the smallest clinical setting while maintaining diagnostic confidence. Click for more info



IBA's stock shot up to a six-month high after the announcement, Reuters reports, rising more than 31 percent and hitting 6.31 euros per share in trading Monday.

Although IBA owns 40 percent of the new company, it will reap 60 percent of the profits for drugs currently under development, in recognition of its past R&D investments, the Belgian company said. In the pipeline are imaging tracers to help diagnose kidney disease and Alzheimer's disease. The development costs of the in-the-works drugs now would be shared equally, the companies said.

Renaud Dehareng, the radiopharmaceutical group's former president, will helm the new entity as CEO, IBA said.

IBA's molecular imaging group employs 1,000 people, has 57 nuclear medicine sites in Europe, the United States and Asia, and runs a manufacturing facility in France. It generates about 175 million euros ($222 million) in yearly revenues, IBA said.

In a separate announcement, IBA said Olivier Legrain, the current chief strategic officer, would be promoted to chief operating officer in preparation for when he takes the reins from CEO Pierre Mottet, who's stepping down in May. However, Mottet will continue with the company as vice-chairman of the board.

IBA, which also makes cyclotrons for proton therapy treatments, is headquartered in Louvain-la-Neuve, Belgium.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED